<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title> HNN215 Week 3 3pm by </title>
      <link>https://padlet.com/sarahd59/wvmwopj6o88ad218</link>
      <description>Management of patients experiencing cardiovascular symptoms (1)</description>
      <language>en-us</language>
      <pubDate>2023-07-23 07:41:02 UTC</pubDate>
      <lastBuildDate>2026-02-26 00:08:47 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Significant drug-drug interactions???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670896</link>
         <description><![CDATA[<div>How / why does it occur?<br>What are they and what signs and symptoms would we see?<br>What do we as nurses do;<br>- prevent and/ or manage these?</div>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/5468cc596a1e96fb7ef8bb856aeb41fd/image.png" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670896</guid>
      </item>
      <item>
         <title>Compare and contrast the significant risks for each of the drug classes</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670897</link>
         <description><![CDATA[<div>What were your significant risks? Why are they significant?<br>Do you understand the MoA of how the patient might develop the risk?<br>Did you need to go and look them up again? </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670897</guid>
      </item>
      <item>
         <title>Part 2???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670898</link>
         <description><![CDATA[<div>This will be added once we get to it :)</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670898</guid>
      </item>
      <item>
         <title>Consider???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670899</link>
         <description><![CDATA[<div><strong><mark>Note: Always consider:<br>Is there anything in the patient's condition/ past history that may increase the risks?</mark></strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670899</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670900</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670900</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670901</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670901</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670902</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670902</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670903</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670903</guid>
      </item>
      <item>
         <title>Case Scenario</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670904</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/05efcb840cc312d459126d8716e4f5c9/image.png" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670904</guid>
      </item>
      <item>
         <title>Scenario continued</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670905</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/a58b854d34acc9f4dbef7a9c1311b785/image.png" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670905</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670906</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/1347252eeb81b9c31d64311a92a5a2d5/HNN215_week_3_NIMC_2023.pdf" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670906</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670907</link>
         <description><![CDATA[<div><strong>Metoprolol<br>Class: </strong>Beta blockers<strong><br>MOA: </strong>block beta receptors- lower heart rate, contractility, electrical conduction<strong><br>Indications for use: </strong>HTN, AF, Angina<strong><br>Signs &amp; symptoms: <br>- </strong>Bradycardia<br>- fatigue<br>- impotence<br>- low BP<br>- heart failure<br>- AV blocks<br><br><strong>Drug interaction: amidarone<br><br>How to identify, prevent or manage risks/nursing considerations: <br>- </strong>monitor heart rate<br>- BP<br>- educate<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670907</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670908</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/82f88f287cdc12915a1eef7168bb3416/IV_Orders_week_3_2023.pdf" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670908</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670909</link>
         <description><![CDATA[<div><strong>Amlodipine<br>Class: </strong>calcium channel blocker <strong><br>MOA: </strong>&nbsp;<br>- Block inward current of calcium into cells in vascular smooth muscle, myocardium and cardiac conducting system via L‑type calcium channels.<strong><br>Indications for use:</strong><br>- hypertension <br>- angina <strong><br>Signs &amp; symptoms:<br></strong>- nausea<br>- headache<br>- flushing <br>- dizziness<br>- hypotension <br>- peripheral oedema <strong><br>How to identify, prevent or manage risks/nursing considerations:<br></strong>- monitor BP, cardiac rhythm, adjust the dose range to the theraputic range<br>- educate patient on healthy food choices and lifestyle (low sodium diet, avoid smoking)&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670909</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670910</link>
         <description><![CDATA[<div><strong>Amiodarone<br>Class: </strong>Class III Antiarrhythmic<strong><br>MOA: </strong>Blocks potassium currents that cause repolarisation of the heart muscles which regulates heart rhythm.<strong><br>Indications for use: <br></strong>- Recurrent hemodynamically unstable ventricular tachycardia <br>-Recurrent ventricular fibrillation<br>Signs &amp; symptoms:<br>- Lung or liver problems<br>-N+V<br>-Shortness of breath<br>-Coughing up blood<br>-Dark urine<br>-Yellowing of eyes and skin<strong><br>How to identify, prevent or manage risks/nursing considerations:<br>-</strong>Monitor EKG (Electrocardiogram) during IV infusion and PO therapy (As it inhibits electrical currents of the heart muscles)<br>- Monitor RR due to risk of pulmonary toxicity&nbsp;<br>- Can slow down the removal of other drugs from the body e.g: Warfarin</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670910</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670911</link>
         <description><![CDATA[<div><strong>Temazepam<br>Class: </strong>Benzodiazepine<strong><br>MOA: </strong>inhibits effects of GABA throughout the CNS<strong><br>Indications for use: </strong>sedation, insomnia, muscle relaxant, anti anxiety (panic attacks)<strong><br>Signs &amp; symptoms: </strong>drowsiness, confusion, light headedness, hyper-salivation, ataxia, slurred speech<br><strong>Risks: </strong>Dependance, respiratory depression <strong><br>How to identify, prevent or manage risks/nursing considerations:&nbsp;</strong>monitoring dosage, reserve for short term use, monitor withdrawal symptoms, falls risk </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670911</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670912</link>
         <description><![CDATA[<div><strong>Potassium/Magnesium<br>Class: </strong>electrolytes <strong><br>MOA: <br>maintains electrolyte gradient keeping specific concentrations inside and outside the cells<br>potassium - 3.5 to 5.5 mmol/l<br>magnesium - <br>Indications for use: <br></strong>potassium<strong> - </strong>electrolyte imbalance, hypokalemia, certain meds, arrhythmias <strong><br></strong>magnesium - involved with hormone receptor binding, muscle contraction, neural activity, neurotransmitter release, asomotor tone and cardiac excitability <strong><br>Signs &amp; symptoms: <br></strong>Potassium - arrhythmia, GIT disturbances, hyperkalaemia, kidney problems<br>magnesium - nausea, abdominal cramping, diarrhea, hypotension, respiratory depression, hypermagnesemia <strong><br>How to identify, prevent or manage risks/nursing considerations:<br>- </strong>monitor and assess electrolytes levels&nbsp;<br>- monitor ECG<br>- monitor vital signs&nbsp;</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670912</guid>
      </item>
      <item>
         <title>Loading doses</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670913</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/45fab7ff74a57a7b74ecdbb16888dd3a/image.png" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670913</guid>
      </item>
      <item>
         <title>Additional considerations</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670914</link>
         <description><![CDATA[<div>Something to consider : do we need to think about the patient's underlying condition such as renal function/ liver function when giving a loading dose? Or body weight? If so why??</div>]]></description>
         <enclosure url="http://image.slideserve.com/275846/loading-dose-l.jpg" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670914</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670915</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:41:02 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/wvmwopj6o88ad218/wish/2649670915</guid>
      </item>
   </channel>
</rss>
